Patents by Inventor Benjamin Maxime Morin
Benjamin Maxime Morin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141039Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.Type: ApplicationFiled: June 13, 2023Publication date: May 2, 2024Inventors: Dhan Sidhartha CHAND, Zahra JAWAD, Olga IGNATOVICH, Nicola Anne RAMSAY, Spencer CAMPBELL, Beth WENSLEY, Emmanuel Cyrille Pascal BRIEND, K. Mark BUSHELL, Benjamin Maxime MORIN, Veronica Franciszka ILKOW
-
Publication number: 20240141047Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: September 27, 2023Publication date: May 2, 2024Inventors: Dhan Sidhartha CHAND, Nicholas Stuart WILSON, Dennis John UNDERWOOD, Benjamin Maxime Morin
-
Publication number: 20230416397Abstract: The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF?-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: May 26, 2023Publication date: December 28, 2023Inventors: Nicholas S. WILSON, Jeremy D. Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
-
Patent number: 11718669Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.Type: GrantFiled: August 10, 2022Date of Patent: August 8, 2023Assignee: AGENUS INC.Inventors: Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
-
Patent number: 11692042Abstract: The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF?-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: March 8, 2019Date of Patent: July 4, 2023Assignee: AGENUS INC.Inventors: Nicholas Stuart Wilson, Jeremy Dale Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
-
Publication number: 20230014036Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.Type: ApplicationFiled: August 10, 2022Publication date: January 19, 2023Inventors: Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
-
Publication number: 20220275049Abstract: Provided are novel antigenic polypeptides comprising tumor-associated peptides, and compositions comprising the same. Such antigenic polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions.Type: ApplicationFiled: January 24, 2022Publication date: September 1, 2022Inventors: Benjamin Maxime MORIN, Mark Arthur FINDEIS, Bishnu JOSHI
-
Publication number: 20220257733Abstract: Provided are novel antigenic polypeptides comprising tumor-associated peptides, and compositions comprising the same. Such antigenic polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using the polypeptides and compositions, methods of treating a disease using the polypeptides and compositions, kits comprising the polypeptides and compositions, methods of making the compositions, and antibodies and T cell receptors that specifically bind to the polypeptides.Type: ApplicationFiled: January 24, 2022Publication date: August 18, 2022Inventors: Dennis John UNDERWOOD, Paisley Trantham MYERS, Erin Denise JEFFERY, Matthew Joseph PEREZ, Benjamin Maxime MORIN, Mark Arthur FINDEIS, Bishnu JOSHI
-
Publication number: 20220235349Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: December 30, 2021Publication date: July 28, 2022Inventors: Yanping Xiao, Nicholas Stuart WILSON, Benjamin Maxime MORIN, Mark Arthur FINDEIS, Cornelia Anne MUNDT, Marc van DIJK, Dhan Sidhartha CHAND, David Adam SAVITSKY, Dennis John UNDERWOOD, Olga IGNATOVICH
-
Publication number: 20220106581Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: July 19, 2021Publication date: April 7, 2022Applicants: AGENUS INC., AGENUS INC.Inventors: Yanping XIAO, Nicholas Stuart WILSON, Benjamin Maxime MORIN, Mark Arthur FINDEIS, Cornelia Anne MUNDT, Marc van DIJK, Dhan Sidhartha CHAND, David Adam SAVITSKY, Dennis John UNDERWOOD, Olga IGNATOVICH
-
Publication number: 20220089732Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: April 26, 2021Publication date: March 24, 2022Inventors: Dhan Sidhartha CHAND, Nicholas Stuart WILSON, Dennis John UNDERWOOD, Benjamin Maxime MORIN
-
Patent number: 11242385Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: April 12, 2018Date of Patent: February 8, 2022Assignee: AGENUS INC.Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
-
Publication number: 20220008527Abstract: Provided are polypeptides and compositions comprising novel HSP-binding peptides. Such polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions.Type: ApplicationFiled: June 17, 2021Publication date: January 13, 2022Inventors: Mark Arthur FINDEIS, Benjamin Maxime MORIN, Bishnu JOSHI
-
Patent number: 11098117Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: November 10, 2020Date of Patent: August 24, 2021Assignee: Agenus Inc.Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
-
Patent number: 11065317Abstract: Provided are polypeptides and compositions comprising novel HSP-binding peptides. Such polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions.Type: GrantFiled: April 25, 2019Date of Patent: July 20, 2021Assignee: AGENUS INC.Inventors: Mark Arthur Findeis, Benjamin Maxime Morin, Bishnu Joshi
-
Patent number: 11021537Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: May 1, 2018Date of Patent: June 1, 2021Assignee: AGENUS INC.Inventors: Dhan Sidhartha Chand, Nicholas Stuart Wilson, Dennis John Underwood, Benjamin Maxime Morin
-
Publication number: 20210106693Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: November 10, 2020Publication date: April 15, 2021Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
-
Publication number: 20200000905Abstract: Provided are polypeptides and compositions comprising novel HSP-binding peptides. Such polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions.Type: ApplicationFiled: April 25, 2019Publication date: January 2, 2020Inventors: Mark Arthur Findeis, Benjamin Maxime Morin, Bishnu Joshi
-
Publication number: 20190352418Abstract: The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF?-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: March 8, 2019Publication date: November 21, 2019Inventors: Nicholas Stuart Wilson, Jeremy Dale Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell